Lead Investigator: Vitalay Fomin, YAI, Inc.
Title of Proposal Research: 2024 DataWorks! Prize: Analyzing COVID-19 Drug Approval and Patient Response Using Historical Data
Vivli Data Request: 10443
Funding Source: None
Potential Conflicts of Interest: None
Summary of the Proposed Research:
We plan to use the clinical data from COVID19 datasets in order to test if some of the drugs that were tested to treat COVID19 could have been approved earlier and faster by identifying the patients who would benefit from the drug the most. We plan to use multiple computational approaches that would look into finding which patients responded the best to a drug. These computational methods uses algorithms and numerical methods to solve a multitude of problems, such as hypothesis testing, statistical modelling and to show relationships between variables and make predictions, in our case, predictions on who could benefit from the drug. This analysis will try to identify biomarkers (measurable lab results or clinical data like age race and Body Mass Index (BMI)) that could be used to find patients that have exceptional response to the treatment, therefore approving the trials faster and bringing the medications earlier to those patients.
Requested Studies:
Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)
Data Contributor: Montreal Heart Institute
Study ID: NCT04322682
Sponsor ID: MHIPS-2020-01
Attrition of TEAEs: Post Hoc Pooled Analysis
Data Contributor: Salix Pharmaceuticals
Study ID: Attrition of TEAEs: Post Hoc Pooled Analysis
Sponsor ID: Attrition of TEAEs: Post Hoc Pooled Analysis
An Open-label, Randomized Controlled Trial of Hydroxychloroquine and Azithromycin for COVID-19 Infection on Hospitalized, Noncritical Patients
Data Contributor: HCor Research Institute
Study ID: NCT04322123
Sponsor ID: Brazil COVID Coalition I Trial
International Registry of Healthcare Workers Exposed to COVID-19 Patients
Data Contributor: Certara
Study ID: NCT04626076
Sponsor ID: CER-HCW-001
COVID-19: Pulmonary Vascular Endothelialitis, Thrombosis and Angiogenesis
Data Contributor: Hannover Medical School
Study ID: Hannover Medical School
Sponsor ID: Hannover Medical School
An Adaptive Phase I/II Randomized Placebo-controlled Trial to Determine Safety, Immunogenicity and Efficacy of Non-replicating ChAdOx1 SARS-CoV-2 Vaccine in South African Adults Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV
Data Contributor: Vaccines & Infectious Diseases Analytics Research Unit, Wits Health Consortium
Study ID: NCT04444674
Sponsor ID: ChAdOx1 nCoV-19_ZA_phI/II v4.1
Efficacy and Safety Study of Nitazoxanide (NTX) in the Treatment of Patients With SARS-CoC-2 Virus Infection (COVID-19). A Pilot, Randomized, Simple Blind, Placebo-controlled, Parallel-group Study
Data Contributor: Hospital Universitario Australia
Study ID: NCT04463264
Sponsor ID: NTZ-COVID ARG1
CKD Risk Prediction among Obese Living Kidney Donors
Data Contributor: The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham
Study ID: DK113980
Sponsor ID: DK113980
Immunotherapy may protect cancer patients from SARS-CoV-2 infection
Data Contributor: Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
Study ID: Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
Sponsor ID: Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
Efficacy of Novel Agents for Treatment of SARS-CoV-2 Infection Among High-Risk Outpatient Adults: An Adaptive Randomized Platform Trial
Data Contributor: University of Washington
Study ID: NCT04354428
Sponsor ID: STUDY00009878
Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): a Blinded, Randomized Study
Data Contributor: University of Washington
Study ID: NCT04328961
Sponsor ID: STUDY00009750
Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization
Data Contributor: University of Minnesota
Study ID: NCT04311177
Sponsor ID: SURG-2020-28683
Comparison of the Efficacy and Safety of Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune) Plasma Among Outpatients With Symptomatic COVID-19
Data Contributor: Johns Hopkins University
Study ID: NCT04373460
Sponsor ID: IRB00247590